RNA Therapeutics Near A Tipping Point, Says Silence’s CEO

With recent product approvals and the development of new chemistries and delivery technologies, the RNA-based drugs sector is undergoing rapid change, and UK-based Silence Therapeutics is aiming to be part of that evolution.